Jan van de Winkel, Ph.D
Jan van de Winkel, Ph.D Chairman of the Board
Jan van de Winkel, Ph.D., is President and Chief Executive Officer of Genmab A/S, which he co-founded in Feb 1999. Genmab is a leading international biotechnology company focused on developing innovative antibody products for the potential treatment of cancer. Dr. van de Winkel has overseen the creation and development of a number of human antibodies for the treatment of cancer and other life-threatening and debilitating diseases. The first approved antibody, Arzerra, received regulatory authorization by the United States FDA [Oct 2009] and the European Medicines Agency [April 2010] for therapy of refractory chronic lymphocytic leukemia.
Dr. van de Winkel is widely recognized as one of the leading scientists in the study of antibodies and their interaction with the immune system. Dr. van de Winkel has (co-) authored more than 300 scientific publications and has been responsible for over 40 patents and patent applications. He holds a Professorship in Immunology at Utrecht University. Prior to joining Genmab, Dr. van de Winkel served as Vice President and Scientific Director of Medarex Europe. He is a member of the board of directors of ISA Pharmaceuticals, the scientific advisory board of Thuja Capital Healthcare Fund and the advisory board of Capricorn Health-tech fund. He holds M.S. and Ph.D. degrees from the University of Nijmegen.
David E. Housman, Ph.D
David Housman is a Ludwig Professor of Biology, Massachusetts Institute of Technology. He is a member of both the National Academy of Sciences (USA) and the Institute of Medicine of the National Academy of Sciences (USA). He has won awards for teaching at MIT and for his innovative contributions in the field of biotechnology. His current work includes the utilization of in vivo testing systems for the identification of targets and small molecules which effect Huntington's disease pathology, the development of strategies for the understanding and effective treatment of myotonic dystrophy as well as the study of complex trait genetics for neurodegenerative and cardiovascular disease.
Currently, he has a research program with Dr. Anne B. Young and her team at MIND, the MassGeneral Institute for Neurodegenerative Diseases, Massachusetts General Hospital, Harvard University Medical School. Together they are working to find new treatments and cures for Huntington's disease with the help of the pharmaceutical company, Novartis.
David Housman founded Integrated Genetics in 1980, which was acquired by Genzyme in 1989. His biotechnology company brought DNA based diagnostics into an accessible setting for clinical use as well as developing a number of useful, biologically based therapeutics, including recombinant human fertility hormones.
He received both his B.A. and Ph.D. from Brandeis University in 1966 and 1971, respectively. His Ph.D. was in molecular genetics. He has contributed to the mapping, identification and functional characterization of genes for many human genetic disorders and phenotypes including the genes for Wilms tumor, myotonic dystrophy, Huntington's disease, familial melanoma as well as elucidating the role of the gene c-kit in hematopoietic stem cell function and the multidrug resistance genes in tumor cell biology. His laboratory has participated in the development of innovative genomic technologies which have played a key role in the advancement of the Human Genome Project and the discovery of genes responsible for genetically-based human diseases.
Tom Schwarz is a partner of Life Sciences Fund Amsterdam, an independent venture capital fund focusing on early stage companies and (university) spin-outs in the biotechnology and biomedical field with a presence in the Amsterdam Area. Tom co-founded the Fund in 2009 after he had co-founded a similar university venture capital fund in Rotterdam, the Erasmus MC Biomedical Fund in 2007. Tom started his venture capital career in 1998, when he co-founded Life Sciences Partners (LSP), a leading European life sciences venture capital fund. Tom has strong contacts within the academic and pharmaceutical community. Tom, a pharmacist by training, gained his experience in the life sciences industry as a CEO of U-Gene Research, a contract research organization in the Netherlands, which he sold in 1997 to Kendle (US).
Tom has led a number of investment processes, including Sequenom, Introgene, Santarus, Skyline, River Diagnostics, ArGENX and AIMM Therapeutics and has held board positions at most of these companies. Four of the investments which Tom played a role in, have since gone public, i.e. Crucell, Santarus, Sequenom and DeVGen. Furthermore, Tom has extensive experience with start-up companies, e.g. he was actively involved in the founding and management of several biotech start-ups, particularly regarding strategy development, fundraising, and creating exits.